Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.01, moving 8.03% from the previous trading session.
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generate significant revenue before 2030.
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Recursion Pharmaceuticals NASDAQ: RXRX outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028.
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
